Overview and Scope
A medical food for inborn errors of metabolism refers to dietary supplements provided to people with genetic conditions that influence their metabolic functions. The dietary requirements of people with these diseases are managed, and these items provide particular nutrients.
Sizing and Forecast
The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $2.72 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to global health initiatives, increased recognition of nutritional therapies, precision medicine approaches, increasing incidence of metabolic disorders, personalized digital nutrition platforms.
The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $4.83 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to telehealth integration, rising demand for clean label products, expanded newborn screening programs, patient-centric care models, plant-based and sustainable formulations. Major trends in the forecast period include technological advancements in genetic testing, advancements in food processing technologies, innovations in ingredient technology, technological advancements in food formulation.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/medical-foods-for-inborn-errors-of-metabolism-global-market-report
Segmentation & Regional Insights
The medical foods for inborn errors of metabolism market covered in this report is segmented –
1) By Product: Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Low Protein Food, Other Products
2) By Diseases: Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Other Diseases
3) By Age Group: Infants, Weaning, Adolescent, Adults
4) By Forms: Powder, Liquids, Gels, Other Forms
5) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies, Other Distribution Channels
North America was the dominant region in the medical foods for inborn errors of metabolism market in 2023. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12161&type=smp
Major Driver Impacting Market Growth
The rise in genetic (inherited) disorders is expected to propel the growth of medical foods for inborn errors in the metabolism market going forward. Genetic (inherited) disorders refer to a disease that is entirely or partially brought on by a deviation from the typical DNA sequence. Medical foods are essential for infants with metabolic abnormalities to deliver specialized nutrition created to address the unique metabolic requirements of people with these illnesses, thereby assisting in the prevention of nutritional deficits and metabolic needs for promoting their growth and well-being. For instance, in May 2021, according to Medline Plus, a US-based online information service produced by the United States National Library of Medicine, the incidence of a gene variant each year in the United States diagnoses 1 in 200,000 individuals with syndrome A. Around the world, 15,000 patients with syndrome B have been diagnosed. Therefore, the rise in genetic (inherited) disorders is driving the growth of medical foods for inborn errors of metabolism market.
Key Industry Players
Major companies operating in the medical foods for inborn errors of metabolism market report are BASF SE, Abbott Laboratories Inc, Danone SA, Bristol-Myers Squibb Co, Meiji Holdings Co Ltd., Nestlé Health Science S.A., Ajinomoto Corporation, Mount Sinai Health System, BioMarin Pharmaceutical Inc, Gerber Products Company, Metagenics Inc., Vitaflo International, SHS International Limited, Merck $ Co Inc., Galen Medical Group, Applied Nutrition Corp., Primus Pharmaceuticals Inc., Reckitt Benckiser Group Plc, Ener-G Foods Inc, Pristine Organics Pvt. Ltd., Cymbiotika LLC, BC Children’s Hospital, NutriScience Innovations LLC, Solace Nutrition LLC
The medical foods for inborn errors of metabolism market report table of contents includes:
1. Executive Summary
2. Medical Foods For Inborn Errors Of Metabolism Market Characteristics
3. Medical Foods For Inborn Errors Of Metabolism Market Trends And Strategies
4. Medical Foods For Inborn Errors Of Metabolism Market – Macro Economic Scenario
5. Global Medical Foods For Inborn Errors Of Metabolism Market Size and Growth
….
32. Global Medical Foods For Inborn Errors Of Metabolism Market Competitive Benchmarking
33. Global Medical Foods For Inborn Errors Of Metabolism Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Medical Foods For Inborn Errors Of Metabolism Market
35. Medical Foods For Inborn Errors Of Metabolism Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
